0055] The various illustrative slings described herein may be employed with any suitable sling delivery system. By way of example, the slings of the invention may be employed with any delivery systems appropriate for treating urinary incontinence. Such delivery systems include, for example, those delivery systems configured for supra-pubic, pre-pubic, transvaginal or transobturator approaches. Without limitation, exemplary delivery systems, methodologies, sling, sling attachments that may be employed can be found in U.S. patent application Ser. No. 10/460,112, U.S. patent application Ser. No. 10/093,498, U.S. patent application Ser. No. 09/916,983, U.S. patent application Ser. No. 10/093,398, U.S. patent application Ser. No. 10/093,450, U.S. patent application Ser. No. 10/094,371, U.S. patent application Ser. No. 10/092,872, U.S. patent application Ser. No. 09/916,983, U.S. provisional patent application Ser. No. 60/465,722, U.S. patent application Ser. No. 10/094,352, U.S. patent application ...
Korean Intellectual Property Office 209 854 Extension of the Patent Prosecution Highway Pilot Program between the USPTO and the CIPO 210 855 Revised Requirements for Requesting Participation in the Patent Prosecution Highway Pilot Program in the USPTO (between the USPTO and the EPO) 211 858 Patent Prosecution Highway Pilot Program between the United States Patent and Trademark Office and the Danish Patent and Trademark Office 212 864 Extension Of the Patent Prosecution Highway Pilot Program Between the USPTO and the UKIPO 213 865 Patent Prosecution Highway Pilot Program between the United States Patent and Trademark Office and European Patent Office 214 869 Patent Prosecution Highway Pilot Program between the United States Patent and Trademark Office and IP Australia 215 874 Patent Prosecution Highway Pilot Program between the United States Patent and Trademark Office and the Korean Intellectual Property Office 216 879 Patent Prosecution Highway Pilot Program between the United States Patent and ...
0001] This application claims priority to U.S. Provisional Patent Application Ser. No. 60/862,743, filed Oct. 24, 2006; and claims priority to and is a continuation of: U.S. Patent Publication No. 20080097908 filed as U.S. Utility patent application Ser. No. 11/876,689 on Oct. 22, 2007; U.S. Patent Publication No. 20080097909 filed as U.S. Utility patent application Ser. No. 11/876,695 on Oct. 22, 2007; U.S. Patent Publication No. 20080097551 filed as U.S. Utility patent application Ser. No. 11/876,708 on Oct. 22, 2007; U.S. Patent Publication No. 20080103554 filed as U.S. Utility patent application Ser. No. 11/876,711 on Oct. 22, 2007; U.S. Patent Publication No. 20080103370 filed as U.S. Utility patent application Ser. No. 11/876,713 on Oct. 22, 2007; U.S. Patent Publication No. 20080097910 filed as U.S. Utility patent application Ser. No. 11/876,719 on Oct. 22, 2007; U.S. Patent Publication No. 20080215360 filed as U.S. Utility patent application Ser. No. 11/876,725 on Oct. 22, 2007; U.S. ...
TY - JOUR. T1 - Patent application trends of induced pluripotent stem cell technologies in the United States, Japanese, and European applications. AU - Morita, Yasushi. AU - Okura, Hanayuki. AU - Matsuyama, Akifumi. PY - 2019/1/1. Y1 - 2019/1/1. N2 - Patent application trends were investigated for induced pluripotent stem cell (iPSC) technologies, particularly disease-specific cell technologies related to iPSCs, in the U.S., Japanese, and European applications during 2017. The number of patent applications for iPSC technologies was 1516 in the United States, 895 in Japan, and 420 in Europe, with 5% of applications for disease-specific cell technologies. In contrast, the percentages of patent applications for iPSC preparation and differentiation technologies were 17% and 23%, respectively. Patent applications for disease-specific cell technologies were classified into four technical fields and 14 disorder groups. In the technical fields, patent applications for genetically engineered cell ...
Trademark is a distinctive logo, phrase, or design such as "Dunkin Donuts®" or "Microsoft®" that uniquely identifies a particular commercial product or series of products with a specific commercial supplier. The symbols ™ or ® are often used to alert the public to the trademark. Anyone claiming ownership of a trademark can use ™ to alert others to their ownership of a trademark. The ® symbol on the other hand indicates that the trademark has been officially registered with the United States Patent and Trademark Office. Federal registration of a trademark is useful in preventing foreign infringement on the trademark and in obtaining registration rights to the trademark outside the United States.. ...
Federal Register: June 15, 1998 (Volume 63, Number 114)] [Notices] [Page 32639-32645] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr15jn98-27] ----------------------------------------------------------------------- DEPARTMENT OF COMMERCE Patent and Trademark Office [Docket No. 980605148-8148-01] Request for Comments on Interim Guidelines for Examination of Patent Applications Under the 35 U.S.C. 112 para. 1 ``Written Description Requirement AGENCY: Patent and Trademark Office, Commerce. ACTION: Notice and request for public comments. ----------------------------------------------------------------------- SUMMARY: The Patent and Trademark Office (PTO) requests comments from any interested member of the public on the following interim guidelines. These guidelines will be used by PTO personnel in their review of biotechnological patent applications for compliance with the ``written description requirement of 35 U.S.C. 112 para. 1. Although the guidelines are ...
OSENI is a trademark of Takeda Pharmaceutical Company Limited registered with the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.. PREVACID is a trademark registered in the U.S. Patent and Trademark Office and SoluTab is a trademark of Takeda Pharmaceuticals U. S. A., Inc. and used under license by Takeda Pharmaceuticals America, Inc.. PREVPAC and PREVACID are trademarks of Takeda Pharmaceuticals U. S. A., Inc. registered in the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.. Rozerem is a trademark of Takeda Pharmaceutical Company Limited registered with the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.. TRINTELLIX is a trademark of H. Lundbeck A/S and used under license by Takeda Pharmaceuticals America, Inc.. ULORIC is a trademark of Teijin Limited registered with the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals ...
49. Use of one of associated or substantially identical trademarks equivalent to use of another.⎯(1) Where under the provisions of this Act. the use a registered trademark is required to be proved for any purpose, the Tribunal may, if and so far as it shall think right, accept the use of a registered associated trademark, or the trademark with additions or alterations not substantially affecting its identity, as an equivalent for the use required to be proved. (2) The use of the whole of a registered trademark shall for the purposes of this Act be deemed to be also a use of any trademark being a part thereof and registered in accordance with sub-section (1) of section 12 of this Act in the name of the same proprietor. 50. Use of trademark for export trade and use when form of trade connection changes :⎯(1) The application in Bangladesh of a trademark to goods or services to be exported from Bangladesh and any other law done in Bangladesh in relation to goods or services, to be so exported ...
The grant and enforcement of patents are governed by national laws, and also by international treaties, where those treaties have been given effect in national laws. Patents are granted by national or regional patent offices.[29] A given patent is therefore only useful for protecting an invention in the country in which that patent is granted. In other words, patent law is territorial in nature. When a patent application is published, the invention disclosed in the application becomes prior art and enters the public domain (if not protected by other patents) in countries where a patent applicant does not seek protection, the application thus generally becoming prior art against anyone (including the applicant) who might seek patent protection for the invention in those countries. Commonly, a nation or a group of nations forms a patent office with responsibility for operating that nations patent system, within the relevant patent laws. The patent office generally has responsibility for the grant ...
Coordinates: 35°40′15.56″N 139°44′45.15″E / 35.6709889°N 139.7458750°E / 35.6709889; 139.7458750 The Japan Patent Office (特許庁, Tokkyochō, JPO) is a Japanese governmental agency in charge of industrial property right affairs, under the Ministry of Economy, Trade and Industry. The Japan Patent Office is located in Kasumigaseki, Chiyoda, Tokyo and is one of the worlds largest patent offices. The Japan Patent Offices mission is to promote the growth of the Japanese economy and industry by administering the laws relating to patents, utility models, designs, and trademarks. (Copyright affairs are administered by the Agency for Cultural Affairs.) The Japan Patent Office is headed by a commissioner and consists of seven departments: General Affairs Department Trademark, Design, and Administrative Affairs Department, in charge of examining trademark right applications, design right applications and formalities check of all applications including patent applications First ...
WASHINGTON (AP) - The Supreme Court on Monday struck down part of a law that bans offensive trademarks, ruling in favor of an Asian-American rock band called the Slants and giving a major boost to the Washington Redskins in their separate legal fight over the team name.. The justices were unanimous in saying that the 71-year-old trademark law barring disparaging terms infringes free speech rights guaranteed in the Constitutions First Amendment.. "It offends a bedrock First Amendment principle: Speech may not be banned on the ground that it expresses ideas that offend," Justice Samuel Alito said in his opinion for the court.. Slants founder Simon Tam tried to trademark the band name in 2011, but the U.S. Patent and Trademark Office denied the request on the ground that it disparages Asians. A federal appeals court in Washington later said the law barring offensive trademarks is unconstitutional and the Supreme Court agreed.. The Redskins made similar arguments after the trademark office ruled in ...
Colombia has reached an agreement with the USPTO to participate in the Patent Prosecution Highway, becoming the first South American country to gain such status. With Colombias sturdy economy and confident move into the global marketplace, this agreement could not come at a better time. Understanding the need for more robust patent laws, the Colombian government is aggressively reshaping its IP system. The authors had the opportunity to meet with Jose Luis Londoño Fernández, Superintendent of Industrial Property (Colombias equivalent to the USPTO). He was enthusiastic about the Colombian patent system and the Patent Prosecution Highway and is eagerly seeking to educate Colombians and the global public about the mechanisms available for protecting their ideas and innovations. Mr. Londoño believes so strongly in patent protection that he is in the process of separating the patent office from the trademark and copyright office to allow the patent department to rapidly expand. Mr. Londoños ...
Association For Molecular Pathology et al v. United States Patent and Trademark Office et al Doc. 203 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ---------------------------------------------------------------------x ASSOCIATION FOR MOLECULAR PATHOLOGY; AMERICAN COLLEGE OF MEDICAL GENETICS; AMERICAN SOCIETY FOR CLINICAL PATHOLOGY; COLLEGE OF AMERICAN PATHOLOGISTS; HAIG KAZAZIAN, MD; ARUPA GANGULY, PhD; WENDY CHUNG, MD, PhD; HARRY OSTRER, MD; DAVID LEDBETTER, PhD; STEPHEN WARREN, PhD; ELLEN MATLOFF, M.S., ELSA REICH, M.S.; BREAST CANCER ACTION; BOSTON WOMENS HEALTH BOOK COLLECTIVE; LISBETH CERIANI; RUNI LIMARY; GENAE GIRARD; PATRICE FORTUNE; VICKY THOMASON; KATHLEEN RAKER, Plaintiffs, v. UNITED STATES PATENT AND TRADEMARK OFFICE; MYRIAD GENETICS; LORRIS BETZ, ROGER BOYER, JACK BRITTAIN, ARNOLD B. COMBE, RAYMOND GESTELAND, JAMES U. JENSEN, JOHN KENDALL MORRIS, THOMAS PARKS, DAVID W. PERSHING, and MICHAEL K. YOUNG, in their official capacity as Directors of the University of Utah ...
Association For Molecular Pathology et al v. United States Patent and Trademark Office et al Doc. 63 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK --------------------------------------------------------------------------x ASSOCIATION FOR MOLECULAR PATHOLOGY; AMERICAN COLLEGE OF MEDICAL GENETICS; AMERICAN SOCIETY FOR CLINICAL PATHOLOGY; COLLEGE OF AMERICAN PATHOLOGISTS; HAIG KAZAZIAN, MD; ARUPA GANGULY, PhD; WENDY CHUNG, MD, PhD; HARRY OSTRER, MD; DAVID LEDBETTER, PhD; STEPHEN WARREN, PhD; ELLEN MATLOFF, M.S.; ELSA REICH, M.S.; BREAST CANCER ACTION; BOSTON WOMENS HEALTH BOOK COLLECTIVE; LISBETH CERIANI; RUNI LIMARY; GENAE GIRARD; PATRICE FORTUNE; VICKY THOMASON; KATHLEEN RAKER, Plaintiffs, 09 Civ. 4515 (RWS) ECF Case v. UNITED STATES PATENT AND TRADEMARK OFFICE; MYRIAD GENETICS; LORRIS BETZ, ROGER BOYER, JACK BRITTAIN, ARNOLD B. COMBE, RAYMOND GESTELAND, JAMES U. JENSEN, JOHN KENDALL MORRIS, THOMAS PARKS, DAVID W. PERSHING, and MICHAEL K. YOUNG, in their official capacity as ...
Could it be happening!? All it took was a government shutdown to convince Valve to take what looks to be the next step towards Half-Life 3. As spotted by NeoGAF, Valve has registered Half-Life 3 with Europes trademarks office, the OHIM.. Upon visiting the actual European trademark office website and looking up the trademark (#012180394), you can clearly see its legit. Valve apparently registered for the trademark on September 29, 2013, and its currently listed as Computer game software; Electronic game software; Downloadable computer game software via a global computer network and wireless devices; Video game software.. While the trademark appears to be official, Valves actual motivation remains in question. Is Valve actually taking the next step in developing Half-Life 3 or are they merely trying to protect their IP?. Things certainly just got a whole lot more interesting!. ...
CTPLO - China Trademark & Patent Law Office. Peoples Republic of China. 中华人民共和国国家工商行政管理总局商标局 China Trademark Office (CTMO)
Leaps trading strategies pdf #### UNITED STATES PATENT AND TRADEMARK OFFICE TRADEMARK ELECTRONIC SEARCH SYSTEM Macam mana nak mula forex #### Kerridge motor trade systems
Binary options books amazon #### PATENT AND TRADEMARK OFFICES TRADEMARK ELECTRONIC SEARCH SYSTEM Trading and investment strategies in behavioral finance #### Forex widget
Dear minarah, The U.S. Patent and Trademark Office issued the patent for the antiviral combination of the two active ingredients lamivudine and zidovudine, branded as Combivir, on 12 January 1999. The patent number is 5,859,021. The U.S. trademark Combivir for that drug was applied for by Glaxo Group Limited on 20 February 1997 and registered by the Trademark Office on 19 May 1998. Combivir was launched in the USA on 26 September 1997. Hope this answers your question! Regards, Scriptor Sources: M decins Sans Fronti res: Annexes (PDF file) http://www.accessmed-msf.org/upload/ReportsandPublications/492001113146/Annexes.pdf GalaxoSmithKline: Annual Report - Intellectual Property http://www.gsk.com/financial/reports/ar/report/descrip_of_bus/intell_property/intell_prop.html United States Patent and Trademark Office: Patent Database http://patft.uspto.gov/netahtml/PTO/search-bool.html United States Patent and Trademark Office: Trademark Database ...
We asked Sandra Park, a staff attorney with the ACLU Womens Rights Project and one of the lead attorneys on our legal challenge to Myriad Genetics patents on the "breast cancer genes," to answer a few questions about this landmark case. The case is The Association of Molecular Pathology, et al v. Myriad Genetics and will be heard by the Supreme Court on April 15th. Breast Cancer Action is the only breast cancer organization that is a plaintiff in this case. 1. Why did the ACLU decide to take on a legal challenge to human gene patents?. This is the first patent case ever brought by the ACLU, so we studied the issue closely and consulted with many people before deciding to get involved. Ultimately, we realized that gene patents, and the policy of the U.S. Patent and Trademark Office of granting these patents, must be challenged because of the important civil liberties concerns they raise. Gene patents stand in the way of scientific innovation and medical care because they allow the patent holder ...
Trademark and unfair-competition laws are designed to prevent a competitor from selling goods or services under the auspices of another. Trademark law, not copyright law, protects trademarks, service marks, and trade names. Trademarks are legally registered words, names, symbols, sounds, or colors or any combination of these items that are used to identify and distinguish goods from those goods manufactured and sold by others and to indicate the source or origin of the goods (eg, brand names). Examples of commonly recognized trademarks include Time magazine, NBC, and Coca-Cola. A service mark is the same as a trademark except that it
Trademark and unfair-competition laws are designed to prevent a competitor from selling goods or services under the auspices of another. Trademark law, not copyright law, protects trademarks, service marks, and trade names. Trademarks are legally registered words, names, symbols, sounds, or colors or any combination of these items that are used to identify and distinguish goods from those goods manufactured and sold by others and to indicate the source or origin of the goods (eg, brand names). Examples of commonly recognized trademarks include Time magazine, NBC, and Coca-Cola. A service mark is the same as a trademark except that it
The granting and exercise of patent rights should be consistent with the basic goals and interests of the society, particularly promotion and protection of public health.. • There is no single patent system. While recognizing its international obligations, each country should shape its patent law according to its socio-economic needs and objectives, including in relation to public health.. • Although the TRIPs Agreement imposes various constraints, it leaves considerable room for countries to design their national laws to address public health concerns.. • Developing patent rules to improve access to medicines, particularly by the poor, is an important public health objective.. • The improvement of access to medicines requires a pro-competitive approach in several aspects of patent legislation.. • Such an approach should aim, as a priority objective, to ensure that patents are granted on developments that constitute true technical contributions, and that patent rights are not unduly ...
2017 BTG International Ltd. All rights reserved. "See More, Reach Further, Treat Smarter", "Imagine where we can go", and BTG and the BTG roundel logo are trademarks of BTG International Ltd. BTG and the BTG roundel logo are registered trademarks of BTG International Ltd in the US, EU and certain other territories. Bead Block, DC Bead, DC Bead LUMI, LC Bead and LC Bead LUMI are trademarks and/or registered trademarks of Biocompatibles UK Ltd. EKOS and EkoSonic are registered trademarks of EKOS Corporation. GALIL is a trademark of Galil Medical Ltd. PneumRx is a registered trademark of PneumRx, Inc. TheraSphere is a registered trademark of Theragenics Corporation used under license by Biocompatibles UK Ltd. Varithena is a registered trademark of Provensis Ltd. CroFab and DigiFab are registered trademarks of BTG International Inc. Voraxaze is a registered trademark of Protherics Medicines Development Ltd. Lemtrada is a trademark of Genzyme Corporation. Zytiga is a trademark of Johnson & Johnson. ...
Biologics patent applications typically contain large numbers of sequences and various combinations of sequence segments. The process of compiling and annotating these sequence lists can be time consuming at best, and in the worst case, errors may go unnoticed until after the patent application has been published. In fact, a substantial number of published patent applications contain serious errors. Typical errors include cases in which the CDR or variable domain combinations are not unique and unintentionally claimed redundantly within a patent application or a CDR or variable domain definition are not consistent between the patent application text and the sequence listing. Other typical errors are having individual sequences concatenated instead of listed as separate sequences or listing incorrect sequence variants. Genedata Biologics helps to prevent such serious errors by automatically tracking, annotating, processing, and properly formatting all relevant sequences for patent applications. ...
U.S. Patent Office Grants Patent On QPIs Breakthrough PhotoMotion Multi-Imaging Technology Quik Pix Inc. Buena Park, CA (OTCBB SYMBOL: QPIX) announced today that the Company has been granted the Patent on a breakthrough technology, PhotoMotion Multi-Imaging. QPI is a company specializing in high quality photographic imaging and visual marketing technologies. The Patent just awarded covers the technology enabling QPI to combine three or more images into a single color transparency that, as if by magic, changes as the astonished viewer moves past the image. The image moves with the viewer. The illusion is optical and requires no special equipment or other mechanism to create this mystical effect. PhotoMotion Multi-Imaging Technology images combined with text or graphics readily fit into existing light box fixtures creating a visual presentation that is so amazing and distinct that PhotoMotion stands to revolutionize the imaging for most backlit advertising displays used in tradeshows, point of ...
Downloadable! Economists and policy makers have long recognized that innovators must be able to appropriate a reasonable portion of the social benefits of their innovations if innovation is to be suitably rewarded and encouraged. However, this paper identifies a number of specific fact patterns under which the current U.S. patent system allows patent holders to capture private rewards that exceed their social contributions. Such excessive patentee rewards are socially costly, since they raise the deadweight loss associated with the patent system and discourage innovation by others. Economic efficiency is promoted if rewards to patent holders are aligned with and do not exceed their social contributions. This paper analyzes two major reforms to the patent system designed to spur innovation by better aligning the rewards and contributions of patent holders: establishing an independent invention defense in patent infringement cases, and strengthening the procedures by which patents are re-examined after
In a recent decision dated 26th June, 2018, the Assistant Controller of Patents and Designs exercised his power under Section 15 of the Patents Act, 1970 ("the Act") and rejected the bid for a patent application. Below, I give a brief description of the patent application and the reasons which led the Controller to come to such a decision, before analyzing the final order.. About the Patent Application. The applicant, Bayer Intellectual Property Gmbh (Initially, Bayer Animal Health Gmbh was the applicant and they later assigned their patent rights to the present applicant), had applied for patent application number 9382/DELNP/2010 for a pharmaceutical invention entitled "Use of nifurtimox for treating giardiasis" on 31st December, 2010. A perusal of the abstract, claims and full description reveals that the said application proposed several compositions containing nifurtimox and an anthelmintic (anti-parasitic drug) for treatment of giardiasis (a particularly nasty intestinal infection caused by ...
However, it should be noted that there are exceptions that may justify a trademarks not having been in genuine use for five years following its registration. Section 26(1) of the act provides that, in certain circumstances, the trademark owner can show legitimate cause for not using a trademark. For example, the trademark owner may not use the relevant trademark in relation to pharmaceuticals for which the registration and validation process takes a long time and prevents the product from being placed on the market; or in relation to products which are typically sold only in holiday seasons such as Christmas and Easter. It is self-evident that such products are not sold throughout the year, but rather are sold only in the respective season (yet in large amounts ...
|p|Okay you came up with a great business name or logo. You want to use it as your companys trademark (or service mark if you offer services). How do you make sure youre not infringing another trademark owners rights? How do you file a federal trademark application? How do you do a trademark search? Learn trademark principles and protect your name.|/p|
Cinderella is a Walt Disney Character ©Disney. 101 Dalmatians is a Walt Disney Movie ©Disney. Donald Duck is a Walt Disney Character ©Disney. Hello Kitty is a trademark of SANRIO CO. LTD. Mickey Mouse is a Walt Disney Character ©Disney. Shrek is a trademark of DreamWorks SKG. SNOOPY is trademark by PEANUTS WORLDWIDE, LLC. Garfield is a trademark of Paws, Inc. Snow White is a character of © Disney. Spider-Man is a registered trademark of Marvel Characters, Inc.. SpongeBob is a trademark of Nickelodeon. "Superman" is a registered trademark of DC Comics. Toy Story is a registered trademarks of Disney Enterprises, Inc.. Winnie the Pooh and all related characters and elements are trademarks of © Disney. "Dora the Explorer" and characters are a registered trademark of Nickelodeon and Viacom.. THE MR MEN are trademarks of THOIP (a Chorion company). Transformers is a registered trademark of the Hasbro company. Hannah Montana and all related characters and elements belong to © Disney. Teenage ...
You have asked for our legal opinion on the patentability of inventions claimed in U.S. patent applications 07/716,831, filed June 21, 1991 (the 831 application, or .831), 07/837,195, filed September 25, 1992 (195), and 07/952,911, filed February 12, 1993 (.911), all filed in the name of Craig Venter and others and assigned to the National Institutes of Health (NIH). We understand that NIH has abandoned these patent applications and has no present intention of filing similar applications in the future, but that NIH remains interested in the patenting of human DNA sequences from a broader public policy perspective. We have therefore attempted to focus on issues that are likely to recur in other patent applications filed by other people and institutions involved in DNA sequencing rather than on questions that are peculiar to the facts of these particular applications. Nonetheless, we preface this opinion letter with the caution that the facts of each patent case are unique. We have before us for
BPAI Board of Patent Appeals and Interferences Patent and Trademark Office (P.T.O.) *1 DE SOLMS v. SCHOENWALD ET AL. Patent Interference No. 101,698 - IP Mall
BPAI Board of Patent Appeals and Interferences Patent and Trademark Office (P.T.O.) *1 DE SOLMS v. SCHOENWALD ET AL. Patent Interference No. 101,698 - IP Mall
BPAI Board of Patent Appeals and Interferences Patent and Trademark Office (P.T.O.) *1 DE SOLMS v. SCHOENWALD ET AL. Patent Interference No. 101,698 - IP Mall
RetroSense Therapeutics, a biotechnology company dedicated to developing gene therapy approaches to vision restoration, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. patent application (No....
As the battle rages over threats to the Internet architecture, a recent publication over the Patent Application for Domain Name Transfers by Verisign is disturbing for those who advocate an open and free Internet. The Application is based on an immediate and direct threat towards an open and free Internet. Just in case people are tempted to think that this was a prank given that they filed it on the 1 April 2011, searches at the United States Patents and Trademark Office (USPTO) reveals that this is a legitimate application .
Melior Discovery receives patent approval from U.S. Patent & Trademark Office for new Parkinsons disease drug candidate. Patent to cover repositione
patents resume This patent resulted from a continuation application of U.S. patent application Ser. No. 10/788,557, filed Feb. Business Report.? 27, 2004 now abandoned; which is a continuation of U.S. Tire Conversion Chart? patent application Ser.. No. 10/437,650 (now U.S. Pat. No. 6,718,345), filed May 13, 2003; which is a continuation of Business Report Example-Of-A U.S. patent application Ser. Sample? No. 10/121,247 (now U.S. Pat. Format Of A Report. Sample Report? No. 6,564,188), filed Apr. Report-Format By Vishal? 10, 2002; which is a continuation of U.S. patent application Ser.. No. Format Of A Business Report. Business? 09/054,339 (now U.S. Pat. No. For Career Change? 6,718,340), filed Apr. 2, 1998; which is a continuation of U.S. patent application Ser. No. 08/597,359 (now U.S. Pat. No. 5,758,324), filed Feb.. 8, 1996; which in Of A Sample Business Example-Of-A, turn claims priority from U.S. Provisional Application Ser. No. 60/008,700, filed Dec. 15, 1995; all of which are incorporated ...
Ah silly patents. Remember back when British Telecom thought that it held a patent on hyperlinks? And then thereve been multiple different patents claiming ownership of the idea of putting an image on a website. Well, it appears that a company in Singapore has recently merged the two ideas into its own patent, and boy, is it ever ready to sue just about everyone. Slashdot points us to the news that Singaporean image search firm Vuestar Technologies claims to hold a patent on linking images from a website to another site and is sending out threatening letters to a bunch of websites. No one has linked to the actual patent so its difficult to see what it really covers -- but the idea that a recent patent would cover the concept of linking images seems preposterous ...
ROCKVILLE, Md., Oct. 31, 2016-- Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that it has received a notice of allowance from the United States Patent and Trademark Office for a patent for claims related to the synthesis of its novel anti-cancer...
BPAI Board of Patent Appeals and Interferences Patent and Trademark Office (P.T.O.) *1 EX PARTE PATRICK CHUNG-SHU KUNG AND GIDEON GOLDSTEIN Appeal No. 88-0962 - IP Mall
As with many gene patents, the gene patent case Association for Molecular Pathology et al. v. USTPO et al. (Myriad) [3] included both method and product claims, which are affected differently by recent court decisions. On 20 March 2012, a unanimous Supreme Court held in Prometheus v. Mayo (Prometheus) [4] that Prometheus Laboratories claims to methods of optimizing the dosage of drugs to treat gastrointestinal autoimmune diseases do not qualify as patentable subject matter under section 101 of the Patent Act (the section that specifically deals with what types of subject matter are eligible for patenting) [5].. Prometheus itself is not a gene patent case but has important implications for gene patents, especially claims of the method type. Thus, shortly thereafter, the Supreme Court issued a GVR order for the Myriad case [3] in light of their decision in Prometheus. A GVR order means that in one swift motion, the Supreme Court (1) granted review of the Myriad case, (2) vacated the ...
SAN RAMON, Calif., April 11, 2016-- SteadyMed Ltd., a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that the Patent Trial and Appeal Board of the United States Patent and Trademark Office has initiated an inter partes review...
Nonresidents per million: Patent applications are applications filed with a national patent office for exclusive rights for an invention--a product or process that provides a new way of doing something or offers a new technical solution to a problem. A patent provides protection for the invention to the owner of the patent for a limited period, generally 20 years. Figures expressed per million population for the same year ...
Almost half of all European patent applications came from the EPO member states, followed by the US, Japan, China and South Korea. Applications from Europe were on a par with last year, with marked differences among individual countries. Europes growth champions were Belgium and Italy. More modest rises came from Austria, Spain, Switzerland and the UK. Demand from Europes biggest patent applicant, Germany, was stable, while France, the Netherlands and many of the Nordic countries filed fewer applications. Overall, China (and to a lesser extent South Korea) was the main driver of growth in applications at the EPO. Applications from the US dropped considerably (although this was only a correction after the one-off jump in 2015 resulting from a change in US patent law), while Japanese companies filed slightly fewer applications. ...
... - Network Solutions has no knowledge of whether any content on this page violates any third party intellectual property rights. Network Solutions will promptly remove any content reasonably objected to by the Owner of a pre-existing trademark. If you have a Trademark issue, please contact [email protected] ...
... - Network Solutions has no knowledge of whether any content on this page violates any third party intellectual property rights. Network Solutions will promptly remove any content reasonably objected to by the Owner of a pre-existing trademark. If you have a Trademark issue, please contact [email protected] ...
... - Network Solutions has no knowledge of whether any content on this page violates any third party intellectual property rights. Network Solutions will promptly remove any content reasonably objected to by the Owner of a pre-existing trademark. If you have a Trademark issue, please contact [email protected] ...
Not all products and/or indications are available in the US and certain other territories. LC Bead and Bead Block are trademarks and/or registered trademarks of Biocompatibles UK Ltd. EKOS, the EKOS logo, Acoustic Pulse Thrombolysis and EkoSonic are trademarks and/or registered trademarks of EKOS Corporation. TheraSphere® is manufactured for Biocompatibles UK Ltd. TheraSphere is a registered trademark of Theragenics Corporation used under license by Biocompatibles UK Ltd. Varithena is a registered trademark of Provensis Ltd. PneumRx and RePneu are trademarks of PneumRx. PneumRx is a registered trademark in the US and certain other territories. The RePneu Coils are not approved for commercial sale in the United States, and are restricted by US law to investigational use only in the U.S. See more. Reach further. Treat smarter and Imagine where we can go are trademarks of BTG International Ltd. BTG and the BTG roundel logo are registered trademarks of BTG International Ltd. Biocompatibles UK ...
Trademark registration for Makers Mark Seal Upheld: On March 26, 2010 a federal judge ordered an injunction which ended a seven year legal battle. The order was entered by U.S. District Judge John G. Heyburn II in the form of...
Document Type and Number: United States Patent Application 20160312283. Abstract:. This invention generally relates to lncRNAs and methods for diagnosing cardiac pathologies in a subject. The invention also provides methods for treating a cardiac pathology in a subject comprising administering to said subject an effective amount of a modulator of one or more lncRNAs of the invention.. Inventors: Ounzain, Samir (Lausanne, CH) - Pedrazzini, Thierry (Le Mont-sur-Lausanne, CH ...
The case involved a Shenzhen health care products company called Yelaixiang, which had filed the "百度" (Baidu) trademark in 2005 and received approval in 2008. (Almost three years! Another reminder of the problem of long queues at the Trademark Office, which they have already cut down on substantially.). Is Yelaixiang a trademark squatter? Yes, although some specifics are necessary here. They filed in 2005, long after Baidu was a famous company. Some of Baidus trademark filings go back to 2001. I think it would be difficult to argue that Yelaixiang was not aware of Baidus brand when it filed for protection in 2005 - I call that bad faith and trademark squatting. Assuming all this can be proven, of course.. All right, the next bit of relevant information here requires us to talk about product classification. Remember that when you file for trademark protection, you have to specify which products or services you wish to protect. You cannot simply go to the Trademark Office and ask for ...
You came up with what is in your estimation the next best invention. For the purposes of illustration, lets say your invention is a car that boasts a 0-60 mph time of less than 4.0 seconds. The key to your invention is a V-8 engine combined with a smattering of technical features. You visit with your patent attorney, she drafts and files a patent application, and you are eventually awarded a patent. You got what you wanted, right? A patent is a patent.. Not necessarily. As you may know, a patent is a right to exclude others from making, using, selling, offering to sell, or importing your patented invention for a limited period of time (right now 20 years from the day you file your patent application). In exchange for the right to exclude others, your patent must include a detailed disclosure of how to make, use, or perform the invention. As to what your "invention" is exactly, that is defined by the patent claims. The claims define the "scope" of the invention-essentially the boundary of the ...
It comprises the use of D-fagomine or derivatives thereof in the prevention and/or coadjuvant treatment of bacterial infections, as well as to pharmaceutical, veterinary, or food and feed, pet food compositions containing them.
The present invention relates to hard surface cleaning compositions, and their use. It is an object of the present invention to provide a hard surface cleaning composition providing hygiene to a hard surface, whilst being easily positioned onto a hard surface; even a wet surface. The present invention provides a hard surface cleaning composition, which is at least partially transparent or translucent, characterized in that it comprises a surfactant system forming a liquid crystalline phase in the presence of water and biocide material.
angry tapir writes Microsoft is asking the US Patent and Trademark Office to deny Apple a trademark on the name App Store, saying the term is generic and competitors should be able to use it. Apple applied for the trademark in 2008 for goods and services including retail store services featuring...
Apple has had two more trademarks added to their ever growing arsenal today. The US Patent and Trademark office granted Apple the trademarks today for the word
New submitter Drishmung writes Retired Judge Paul Michel, who served on the Federal Circuit 1988-2010 — the court that opened the floodgates for software patents with a series of permissive decisions during the 1990s — thinks software patents are good. Yes, the patent system is flawed, ...
This is unbelievable I have independently to Stephen Wills (the applicant and inventor of the patent application Treating microvasculature diseases with acetyl cholinesterase inhibitors under patent number CA 2597566 A1) concluded the same about treatment of many chronic (including p ...
Patent examiners make up the bulk of the employees at USPTO. They are generally newly graduated scientists and engineers, recruited from various universities around the nation.[citation needed] They hold degrees in various scientific disciplines, but who do not necessarily hold law degrees. Unlike patent examiners, trademark examiners must be licensed attorneys.[citation needed] All examiners work under a strict, "count"-based production system.[18] For every application, "counts" are earned by composing, filing, and mailing a first office action on the merits, and upon disposal of an application. The Commissioner for Patents oversees three main bodies, headed by former Deputy Commissioner for Patent Operations, currently[19] Peggy Focarino, the Deputy Commissioner for Patent Examination Policy, currently[when?] Andrew Hirshfeld as Acting Deputy, and finally the Commissioner for Patent Resources and Planning, which is currently[when?] vacant.[20] The Patent Operations of the office is divided ...
On June 29, 2016, the U.S. Patent and Trademark Office (USPTO) launched a pilot program to provide expedited review of patent applications directed to cancer immunotherapy. Under the new program, a patent application having at least one claim to a method of treating cancer using immunotherapy can be "made special" and advanced out of turn for examination, simply by filing a grantable petition. The program is intended to support the White Houses $1 billion initiative to achieve ten years worth of cancer research in the next five years.. Unlike the USPTOs accelerated examination and Prioritized Examination (Track I) programs, no fees are required to participate in the Cancer Immunotherapy Pilot Program.. To be eligible for the program, a patent application must include at least one claim directed to a method of treating cancer using immunotherapy. According to the USPTO, the claim should encompass "a method of ameliorating, treating, or preventing a malignancy in a human subject wherein the ...
Prous Institute for Biomedical Research has announced the recent publishing of its new WIPO patent application. The cited compounds figured among the new magnolol and honokiol derivatives obtained at the Prous Institute for Biomedical Research that have shown inhibitory activity against multiple protein kinases, including epidermal growth factor receptor (EGFR), proto-oncogene tyrosine-protein kinase Src, cyclin-dependent protein kinase (CDK2), protein kinase C (PKC) and mitogen-activated protein kinase (MAPK 1). The compounds antiproliferative activity (IC50 = 0.9-4.6 mcM) has been demonstrated in brain, colon, liver, ovary, prostate and breast tumor cell lines, as well as melanoma and leukemia cell lines. These novel compounds have potential to suppress tumor growth and/or prevent recurrence of metastasis. In vivo efficacy of the compounds has been proven using tumor xenografts models. Furthermore, analgesic activity of claimed compounds has been observed in experimental animal models of pain ...
The Japanese Patent Office has granted the first patent for induced pluripotent stem cells (iPS cells) to Kyoto University, where researcher Shinya Yamanaka produced both the first non-human iPS cells in 2006 and, using the same process, the first human iPS cells in 2007.The Japanese patent, a limited version of a much broader international patent application covering all forms of iPS cell (excluding germ cells) across all species, covers only human iPS cells created using Yamanakas process based on reprogramming adult cells using four gene factors.. The granting of the patent in Japan was fast-tracked by Patent Office officials so as to make clear the Universitys claim while the broader patent goes through lengthy processing across the worlds other major patent institutions. The urgency in part reflects the contemporaneous progress of a US team headed by James Thomson at the University of Wisconsin which published its own successes in producing human iPS cells on the same day as Yamanaka in ...
First American Scientific Corp (FASC.OB) Announces Approval of Patent Application for Recovery of Fuel from biomass by Japanese Ministry of International Economy and Industry
A 2009 continuation patent application claim lacks adequate written description in a 2000-filed specification despite its description of all claim limitations, the U
American Manganese Inc. (TSX.V: AMY; Pink Sheets: AMYZF): PCT International Patent Application Submitted For Lithium Ion Batteries Recycling Process And Recovery Of Cathode Materials
The European Patent Office Enlarged Board of Appeal yesterday gave its decision on the so-called "broccoli" and "tomato" cases, and excluded "essentially biological processes for the production of plans (or animals)" from patentability.. The Board concluded that "while technical devices or means, such as genetic markers, may themselves be patentable inventions, their use does not make an essentially biological process patentable.". Past IPW coverage here (IPW, Biodiversity/Genetic Resources/Biotech, 21 July 2010).. Non-profit organisations the Berne Declaration and Swissaid praised the decision but said that the EPO was still granting patents on selected materials such as genetic sequences, on technical process and on genetically modified plants and animals. The Berne Declaration calls for a total ban on patents on plants, animals, food derived from plants or animals, and selection processes.. Read the EPO press release here. ...
Cannabics files patent application with PCT authorities on methods for testing therapeutic effectiveness of cannabinoids for cancer patients
Trademarked. By: Ashley Czechowski. Donald Trump has trademarked "Success by Trump" cologne, the "Donald J. Trump Signature Collection" for luggage and shoe-shine kits, and he even held one for "Trump Steaks" until 2014. And John Oliver, well-known comedian is trying to trademark "Drumpf.". Oliver claims "Drumf" is Donald Trumps ancestral family name and he has created the donaldjdrumpf.com website where he sells the "Make Donald Drumpf Again" hats, which are on backorder. It also offers a Chrome browser extension to replace all instances of the word "Trump" with "Drumpf" in a news feed.. Oliver filed a trademark application February 26, 2016 for "Drumpf," and given the processing time of trademarks at the U.S. Patent and Trademark Office, it may take up to four to five months before a preliminary decision is issued. The trademark application was filed by Howard Shire, a partner at Kenyon & Kenyon in New York.. It should be noted that if Trump seeks to object to trademark registration, he may ...
Trademarked. By: Ashley Czechowski. Donald Trump has trademarked "Success by Trump" cologne, the "Donald J. Trump Signature Collection" for luggage and shoe-shine kits, and he even held one for "Trump Steaks" until 2014. And John Oliver, well-known comedian is trying to trademark "Drumpf.". Oliver claims "Drumf" is Donald Trumps ancestral family name and he has created the donaldjdrumpf.com website where he sells the "Make Donald Drumpf Again" hats, which are on backorder. It also offers a Chrome browser extension to replace all instances of the word "Trump" with "Drumpf" in a news feed.. Oliver filed a trademark application February 26, 2016 for "Drumpf," and given the processing time of trademarks at the U.S. Patent and Trademark Office, it may take up to four to five months before a preliminary decision is issued. The trademark application was filed by Howard Shire, a partner at Kenyon & Kenyon in New York.. It should be noted that if Trump seeks to object to trademark registration, he may ...
Health,... PITTSBURGH Jan. 12 /- Mylan Inc. (Nasdaq: ... U.S. Patent No. 7462645 was issued Dec. 9 2008 and is directed... U.S. Patent Nos. 7465756 and 7473710 were issued Dec. 16 2008... In addition Dey has received a Notice of Allowance on yet anoth...,U.S.,Patent,and,Trademark,Office,Issues,Mylans,Specialty,Division,,Dey,L.P.,,Three,Additional,Patents,Protecting,Perforomist(R),Inhalation,Solution,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
GenSpera Receives Patent on Targeted Prostate Cancer Drugs SAN ANTONIO--(BUSINESS WIRE)-- GenSpera, Inc. (OTC.BB: GNSZ) announced that the United States Patent and Trademark Office (USPTO)
November 29/New Delhi, India/Indian Patents News -- Norway based Pharmalogica AS filed patent application for drink formula comprising fresh marine omega-3 oil and antioxidants. The inventors are Mathisen Janne Sande and Mathisen Henrik. Pharmalogica AS filed the patent application on September 22, 2010. The patent application number is 3507/KOLNP/2010 A. The international classification number is A23L 2/52. According to the controller general of Patents, Designs & Trade Marks, "The present invention relates a new drink formula comprising fresh marine omega-3 oil in an emulsion and . . .
Discover FL FASH LAW CECA MAGAN. Data and details about the registered trademark. Patents and trademarks: your reference website on trademarks, patents and designs. This application has been made by CECA MAGAN ABOGADOS, SLP
ALLOSTRUX is a trademark and brand of TEVA Pharmaceutical Industries Limited. Filed to USPTO On Wednesday, August 17, 2016, The ALLOSTRUX covers Pharmaceutical preparations for the treatment of cardiovascular diseases. Search for other trademarks at Trademarkia.
FR of Doc No: 2012-31594] -----------------------. DEPARTMENT OF COMMERCE. United States patent and Trademark office. [Dock No. PTO-P-2012-0052]. Request for Comments and Notice of Roundtable events for Partner-hip for Enhancement of Quality of Software-Related of patent. AGENCY: United States patent and Trademark office, Commerce.. ACTION: Request for comments. Notice of meetings.. ----------------------------. SUMMARY:. The United States patent and Trademark office (USPTO) seeks to form a partner-hip with the software community to enhance the quality of software related of patent (software Partner-hip). Members of the publicly ares invited to participate. The software wants Partner-hip Be in opportunity to bring stakeholders together through a series of roundtable discussions to share ideas, feedback, experiences, and insights on software related of patent. To commence the software Partner-hip and to provide increased opportunities for all to participate, the USPTO is sponsorship two ...
patentpundit writes On April 18, 2008, Apple Computer applied for a patent relating to an invention that allows for showing advertisements within an operating system. The first named inventor on the patent application is none other than Steve Jobs. The patent application published and became avai...
Most patents covering dermatologic products contain patent claims directed to the pharmaceutical formulation of the product. Such patents, known as formulation patents, are vulnerable to attacks based on the legal argument that the formulations covered are obvious over formulations already known prior to the filing of the patent application. Because obviousness is an important concept in patent law, recent court cases concerning obviousness and formulation patents were examined and discussed below. Courts have ruled that patent claims are obvious when features of the claimed formulation are found in the prior art, even if the features or characteristics of the formulation are not explicitly disclosed in the prior art. However, patentees have successfully overcome obviousness challenges where there were unexpected results or properties and/or the prior art taught away from the claimed invention.
Trademark License Agreement - Motorola Trademark Holdings LLC, Motorola Inc. and Motorola Solutions Inc. and Other Business Contracts, Forms and Agreeements. Competitive Intelligence for Investors.
By Richard Stobbe. Inventors must take care that their invention is "new" for it to be patentable. That means the invention hasnt been disclosed to the public. Trade show announcements, press releases, publications, offering the invention for sale - all of these can be considered a public disclosure, and if disclosure of the invention occurs before the date of filing of the patent application, this disclosure could defeat patentability, since the invention is no longer "new" for patenting purposes.. In Canada and the U.S. there is a 12-month grace period, so the date of prior disclosure is measured against this 12-month period: put another way, patentability may be lost if the invention was disclosed by the inventor more than one year before the filing date of the patent.. So how does this apply to experimental use? How can an inventor test new inventions and avoid the problems associated with public disclosure?. The recent decision in Bombardier Recreational Products Inc. v. Arctic Cat Inc. is ...
INK+VOLT is a trademark and brand of Matsudaira, Katherine A. Filed to USPTO On Wednesday, August 17, 2016, The INK+VOLT covers On-line retail store services featuring office supplies; On-line retail store services featuring papers, notebooks, journals, pen holders, binders, paper pockets, tape dispensers, note cards, staplers, pencil cups, calendars, desk pads, mugs, pencils, pens, clips, stickers, usb cables, screen cleaning kits, and stationary. Search for other trademarks at Trademarkia.
Should you file a provisional patent application? Although Patwrite is a full service Intellectual Property Law Firm with corporate clients, we specialize in helping private inventors get legal protection for their intellectual property. Because of this, we hear this question on a daily basis. Most clients want us to tell them what they should do. We really cant make the decision for you, but we can give you the information you need to make an informed decision. First lets look at the history of the provisional patent and just exactly what it is. The provisional patent application (PPA) is a fairly new innovation in the US patent system. It has only been around for about 10 years. Part of the problem that the PPA addresses, is that the US awards patents to the first to invent rather than the first to file used by the rest of the world. It is beyond the scope of this paper to get involved in that debate, but the need to quickly establish a priority date is needed and the provisional ...
A brief review of all of the articles Ive written in these here pages about sweet, delicious alcohol mostly have to do with trademark spats between drink-makers, including many in which Ive made the point that its high time for the USPTO to get a little more subtle when it comes to its alcohol marketplace designations. Beer isnt wine, and wine isnt liquor, and the public looking to buy one of those is quite unlikely to confuse one product for another. The focus of many of those posts was how this lack of distinction between the alcohol markets has resulted in too many aggressive trademark lawsuits and threat letters that hardly seemed necessary. But there is a flip side to all of this that serves as another perfectly good reason for the USPTO to make a change. Recently, one liquor distiller sued another in what seems like a fairly plausible trademark infringement case. ...
In addition to the changes applying for EU trademarks, an EU Certification Mark will be introduced as of 1 October 2017. This new type of trademark at EU level will enable certifying institutions to permit the use of the mark as a sign for goods or services complying with the applicable certification requirements. Certification marks can certify the nature of the goods or services for which they are used. This may include, for example, materials of construction, a method or mode of manufacture of goods or provision of services, accuracy of the goods or services, and any definable characteristic of the goods or services but not the origin of a product since this is covered by Geographic Indications (GIs).. The introduction of EU certification marks will remedy the current inconsistency between national systems and the EU trademark system as not all of the EU Member States allow for certification marks under their national systems. At present, there are a number of territories among the EU member ...
Machinery China, Shoes Silicone Trademarks Heating Pressing Machine, The shoes Silicone Trademarks Heating Pressing Machine is for producing the silicone Trademarks on shoes and leather, al...
BD In-Fusion™ is a trademark of BD Biosciences Clontech; Gateway® is a registered trademark of Invitrogen Life Technologies; LNA™ and Locked Nucleic Acid are trademarks of Exiqon; NASBA® is a registered trademark of bioMerieux; SYBR® is a registered trademark of Molecular Probes, Inc.; TaqMan® is a registered trademark of Roche Molecular Systems, Inc.; TOPO® is a registered trademark of Invitrogen Corporation; MLPA® is a registered trademark of MRC-Holland ...
American trademark law has long operated on the assumption that there exists an inexhaustible supply of unclaimed trademarks that are at least as competitively effective as those already claimed. This core empirical assumption underpins nearly every aspect of trademark law and policy. This Article presents empirical evidence showing that this conventional wisdom is wrong. The supply of competitively effective trademarks is, in fact, exhaustible and has already reached severe levels of what we term trademark depletion and trademark congestion. * * * These data show that rates of word-mark depletion and congestion are increasing and have reached chronic levels, particularly in certain important economic sectors. The data further show that new trademark applicants are increasingly being forced to resort to second-best, less competitively effective marks. Yet registration refusal rates continue to rise. The result is that the ecology of the trademark system is breaking down, with mounting barriers ...
GNU may be a registered trademark of the Free Software Foundation. Linux is a registered trademark of Linus Torvalds. Ubuntu and Canonical are registered trademarks of Canonical Ltd. Debian is a registered trademark of Software in the Public Interest, Inc. And of course Intel is a registered trademark of Intel Corporation, and AMD is a registered trademark of Advanced Micro Devices, Inc. Windows, XP, Vista, Windows 7 and Microsoft Office are registered trademarks of Microsoft Corporation. My research shows that "embrace, extend and extinguish" is not held as a legal trademark by anyone as of yet. Microsoft might want to snatch that up just to round out their portfolio. Hey, Im just sayin... while I am at it, this is a known spammers email address and I am placing it here so his email address will be harvested by other spammers. [email protected] ...
GNU may be a registered trademark of the Free Software Foundation. Linux is a registered trademark of Linus Torvalds. Ubuntu and Canonical are registered trademarks of Canonical Ltd. Debian is a registered trademark of Software in the Public Interest, Inc. And of course Intel is a registered trademark of Intel Corporation, and AMD is a registered trademark of Advanced Micro Devices, Inc. Windows, XP, Vista, Windows 7 and Microsoft Office are registered trademarks of Microsoft Corporation. My research shows that "embrace, extend and extinguish" is not held as a legal trademark by anyone as of yet. Microsoft might want to snatch that up just to round out their portfolio. Hey, Im just sayin... while I am at it, this is a known spammers email address and I am placing it here so his email address will be harvested by other spammers. [email protected] ...
One of the underlying principals and purposes of trademark law is to avoid confusion among the consuming public. Thus, the principal standard applied when there is a conflict between two trademarks (whether in a lawsuit for trademark infringement, in an opposition proceeding, etc.) is whether there is a likelihood of confusion between the two marks - that is, whether consumers are going to be confused.. ...
This product is protected by patent and pending patent applications and their corresponding national rights: FI 20155573, US 7,324,002, US 7,271,774, US 13/794,468, US 13/833,755, US 13/827,418, US 14/195,670, US 14/331,268, US 14/839,928, US 14/882,487.. Additional patent applications have been filed.. The Valencell optical heart rate sensor used in this product is protected by patent and pending patent applications and their corresponding national rights. For further information, please visit valencell.com/patents/.. ...
As you may know, one of the most usual problems in Mexico in connection to patents on medicines has been the lack of communication between the Mexican Patent and Trademark Office (MPTO) and the Ministry of Health (MH). The MH has authority to approve the manufacture, commercialization and importation of medicines in Mexico. No pharmaceutical product can be sold in Mexico without the approval of the MH. In many cases, the MH has authorized products that infringe Mexican patents. For years the MH argued that patent matters were completely out of its jurisdiction, and if there were patent infringement problems, they should be addressed to the MPTO or the courts. This circumstance created a contradictory situation, where a federal government agency such as the MPTO was issuing patents on medicines, granting to the patentee the exclusive right to the use of the invention in Mexico, while the MH was authorizing the commercialization of products that may infringe a patent on a medicine. On September ...
The U.S. Patent & Trademark Office rejected Amarin Corp.s AMRN, -0.27% application for a patent covering an experimental heart drug derived from fish oil, causing the Dublin-based companys American depositary shares to fall as much as 9.5% Wednesday.. The drug, code-named AMR101, would treat high levels of triglycerides, a fatty substance in the blood linked to risk for heart problems. Some observers have projected its annual sales exceeding $2 billion.. Amarin had applied for a U.S. patent covering a method of treating high triglycerides with the active ingredient in AMR101. The PTO, however, issued a final rejection of the application on Aug. 12, according to a docket item on the PTO website.. A copy of the rejection letter wasnt immediately available, and an Amarin spokesman couldnt be reached.. A Canaccord Genuity analyst said in a research note Wednesday that issuance of a patent for AMR101 could be postponed to the second half of 2012, following an appeal by the company.. The PTO had ...
Brian Donahue is a senior patent agent in the Intellectual Property Practice Group of Morrison & Foersters Palo Alto office. Dr. Donahue practices in the area of biotechnology. He has extensive experience in patent drafting and patent prosecution before the United States Patent and Trademark Office, and in coordination of patent prosecution in other jurisdictions in association with foreign patent counsel. He also has substantial expertise in patent portfolio analyses and management, prior art searching, and due diligence inquiries, including freedom-to-operate analysis and intellectual property landscape analysis. Dr. Donahue has worked with a wide range of clients, including startup biotech companies, large pharmaceutical companies, universities, and independent inventors. Representative clients for whom Dr. Donahue has performed patent work for include Childrens Hospital of Oakland Research Institute, Genentech, Genzyme, and VistaGen Therapeutics.. Dr. Donahue has prosecuted patent ...
Downloadable! This paper investigates whether patent fee policies are a potential factor underlying the boom in patent applications observed in major patent offices. We provide the first panel-based evidence suggesting that fees affect the demand for patents in three major patent offices (EPO, USPTO and JPO), with a price elasticity of about -0.4 (similar to that of the residential demand for oil or water). The laxity of fee policies adopted by patent offices over the past 25 years therefore contributed, to a significant extent, to the rising propensity to patent observed since the mid-nineties. This is especially true at the European Patent Office, which has dramatically decreased its fees since the mid-1990s.
Ian Lamont writes The Industry Standard reports that Dell is trying to trademark the term cloud computing . The phrase entered the tech lexicon years ago, but Dells application (serial number 77139082) was made in early 2007 to the US Patent and Trademark Office, apparently in connection with data...
GAITHERSBURG, Md., March 17, 2011 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCBB:CMXI) (the Company or Cytomedix), a leading developer of biologically active regenerative therapies for wound care and tissue repair, today announced that it has received the Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application for the newly-designed AutoloGel™ Separation System. The original provisional patent application was filed as a result of a product development collaboration between Cytomedix and biomechanical engineers in Israel intended to fundamentally redesign the AutoloGel System. The redesign includes proprietary elements that enable a safer and significantly more rapid point-of-care procedure for the physical separation of platelets and plasma from whole blood.
Hermann AM MuckeHM Pharma Consultancy, Vienna, AustriaPurpose: This investigation identifies patent applications published under the international Patent Convention Treaty between July 2010 and January 2011 in three significant fields of vascular risk management (arterial hypertension, atherosclerosis, and aneurysms) and investigates whether the inventors have also published peer reviewed papers directly describing their claimed invention.Results: Out of only 48 patent documents that specifically addressed at least one of the above-mentioned fields, 15 had immediate companion papers of which 13 were published earlier than the corresponding patent applications; the majority of these papers were published by noncorporate patentees. Although the majority of patent applications (30 documents) had at least one corporate assignee, 18 came from academic environments. As expected, medical devices dominated in the aneurysm segment while pharmacology dominated hypertension and atherosclerosis.Conclusion: Although
DUBLIN, IRELAND--(Marketwired - Nov 13, 2015) - Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced the issuance of a Notice of Allowance from the United States Patent and Trademark...